Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Editas Medicine Inc (NASDAQ: EDIT) closed the day trading at $2.5 up 1.21% from the previous closing price of $2.47. In other words, the price has increased by $1.21 from its previous closing price. On the day, 1.67 million shares were traded. EDIT stock price reached its highest trading level at $2.72 during the session, while it also had its lowest trading level at $2.49.
Ratios:
For a better understanding of EDIT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 2.77. In the meantime, Its Debt-to-Equity ratio is 4.05 whereas as Long-Term Debt/Eq ratio is at 3.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 03 ’25 when O’Neill Gilmore Neil bought 7,000 shares for $2.73 per share.
Burkly Linda bought 800 shares of EDIT for $2,184 on Sep 03 ’25. On Aug 07 ’25, another insider, Parison Amy, who serves as the SVP, Chief Financial Officer of the company, sold 679 shares for $2.58 each. As a result, the insider received 1,752 and left with 16,827 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 224800496 and an Enterprise Value of 67434408. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.78 while its Price-to-Book (P/B) ratio in mrq is 11.39. Its current Enterprise Value per Revenue stands at 1.733 whereas that against EBITDA is -0.438.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.12, which has changed by -0.28366762 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $4.12, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is -6.71%, while the 200-Day Moving Average is calculated to be 32.80%.
Shares Statistics:
Over the past 3-months, EDIT traded about 2.47M shares per day on average, while over the past 10 days, EDIT traded about 1044590 shares per day. A total of 89.92M shares are outstanding, with a floating share count of 89.11M. Insiders hold about 0.90% of the company’s shares, while institutions hold 47.45% stake in the company. Shares short for EDIT as of 1755216000 were 8202599 with a Short Ratio of 3.32, compared to 1752537600 on 8516241. Therefore, it implies a Short% of Shares Outstanding of 8202599 and a Short% of Float of 9.140000500000001.
Earnings Estimates
Editas Medicine Inc (EDIT) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.25, with high estimates of $0.11 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.68 and -$2.22 for the fiscal current year, implying an average EPS of -$2.02. EPS for the following year is -$1.03, with 9.0 analysts recommending between -$0.63 and -$1.6.
Revenue Estimates
12 analysts predict $4.94M in revenue for the current quarter. It ranges from a high estimate of $25M to a low estimate of $500k. As of the current estimate, Editas Medicine Inc’s year-ago sales were $61k
A total of 12 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $55.74M, while the lowest revenue estimate was $9.2M, resulting in an average revenue estimate of $20.57M. In the same quarter a year ago, actual revenue was $32.31M
